Table 3.
Estimated Kaplan–Meier events rates of 4-year follow-up
| Adverse events | Overall population | Propensity score-matched population | ||||||
|---|---|---|---|---|---|---|---|---|
| High AIP (n = 937) | Low AIP (n = 1419) | Adjusted HRa (95% CI) | P Value | High AIP (n = 821) | Low AIP (n = 821) | HR (95% CI) | P value | |
| MACCE | 253 (27.0) | 230 (16.2) | 1.638 (1.363–1.969) | < 0.001 | 214 (26.1) | 145 (17.7) | 1.614 (1.303–2.001) | < 0.001 |
| All-cause death | 40 (4.3) | 33 (2.3) | 1.690 (1.049–2.724) | 0.031 | 34 (4.1) | 21 (2.6) | 1.750 (1.003–3.054) | 0.049 |
| Cardiac death | 28 (3.0) | 19 (1.3) | 2.184 (1.197–3.984) | 0.011 | 24 (2.9) | 11 (1.3) | 2.615 (1.251–5.470) | 0.011 |
| Cardiac death/MI | 71 (7.58) | 50 (3.52) | 2.199 (1.531–3.158) | < 0.001 | 58 (7.06) | 30 (3.65) | 1.968 (1.266–3.058) | 0.003 |
| MI | 58 (6.3) | 41 (2.9) | 1.962 (1.301–2.960) | 0.001 | 47 (5.8) | 25 (3.1) | 2.080 (1.267–3.415) | 0.004 |
| Repeat revascularization | 210 (22.9) | 190 (13.5) | 1.644 (1.343–2.013) | < 0.001 | 177 (22.0) | 119 (14.6) | 1.628 (1.285–2.062) | < 0.001 |
| TVR | 125 (13.6) | 99 (7.0) | 1.768 (1.347–2.322) | < 0.001 | 105 (13.1) | 60 (7.4) | 1.809 (1.310–2.498) | < 0.001 |
| Non-TVR | 85 (9.4) | 91 (6.5) | 1.413 (1.043–1.916) | 0.026 | 72 (9.0) | 59 (7.3) | 1.314 (0.927–1.865) | 0.125 |
| Stroke | 23 (2.5) | 27 (1.9) | 1.124 (0.628–2.014) | 0.694 | 20 (2.5) | 17 (2.1) | 1.191 (0.610–2.325) | 0.608 |
Values expressed are n (%) or hazard ratio (95% confidence interval). The percentages shown are Kaplan–Meier estimates from the intention to treat analysis
Major adverse cardiac and cerebrovascular events included cardiac death, myocardial infarction, repeat revascularization, and stroke
AIP atherogenic index of plasma, CI indicates confidence interval, HR hazard ratio, MACCE major adverse cardiac and cerebrovascular event, MI myocardial infarction, TVR target vessel revascularization
aHazard ratio was adjusted with age, body mass index, sex, medical history, medical treatment